ENST00000619238.2:n.-222A>C
Variant names:
Variant summary
Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1
The ENST00000619238.2(CSTL1):n.-222A>C variant causes a upstream gene change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0804 in 152,194 control chromosomes in the GnomAD database, including 650 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: 𝑓 0.080 ( 650 hom., cov: 33)
Consequence
CSTL1
ENST00000619238.2 upstream_gene
ENST00000619238.2 upstream_gene
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -0.220
Publications
9 publications found
Genes affected
CSTL1 (HGNC:15958): (cystatin like 1) The cystatin superfamily encompasses proteins that contain multiple cystatin-like sequences. Some of the members are active cysteine protease inhibitors, while others have lost or perhaps never acquired this inhibitory activity. There are three inhibitory families in the superfamily, including the type 1 cystatins (stefins), type 2 cystatins and the kininogens. The type 2 cystatin proteins are a class of cysteine proteinase inhibitors found in a variety of human fluids and secretions. The cystatin locus on chromosome 20 contains the majority of the type 2 cystatin genes and pseudogenes. This gene is located at the telomeric end of the cystatin locus and encodes a type 2 cystatin-like protein. The specific function of this protein has not been determined. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -12 ACMG points.
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.92).
BA1
GnomAd4 highest subpopulation (AMR) allele frequency at 95% confidence interval = 0.129 is higher than 0.05.
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| CSTL1 | ENST00000619238.2 | n.-222A>C | upstream_gene_variant | 5 |
Frequencies
GnomAD3 genomes AF: 0.0804 AC: 12230AN: 152076Hom.: 648 Cov.: 33 show subpopulations
GnomAD3 genomes
AF:
AC:
12230
AN:
152076
Hom.:
Cov.:
33
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome AF: 0.0804 AC: 12233AN: 152194Hom.: 650 Cov.: 33 AF XY: 0.0805 AC XY: 5988AN XY: 74390 show subpopulations
GnomAD4 genome
AF:
AC:
12233
AN:
152194
Hom.:
Cov.:
33
AF XY:
AC XY:
5988
AN XY:
74390
show subpopulations
African (AFR)
AF:
AC:
877
AN:
41546
American (AMR)
AF:
AC:
2049
AN:
15270
Ashkenazi Jewish (ASJ)
AF:
AC:
188
AN:
3470
East Asian (EAS)
AF:
AC:
12
AN:
5188
South Asian (SAS)
AF:
AC:
331
AN:
4826
European-Finnish (FIN)
AF:
AC:
1038
AN:
10566
Middle Eastern (MID)
AF:
AC:
12
AN:
294
European-Non Finnish (NFE)
AF:
AC:
7471
AN:
68008
Other (OTH)
AF:
AC:
169
AN:
2114
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.499
Heterozygous variant carriers
0
566
1133
1699
2266
2832
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
136
272
408
544
680
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.